Study Comparing Interventional Therapy Plus Medication Versus Medication Alone for Preventing Problems in Non-Flow-Limiting Vulnerable Coronary Plaques

What this Trial Is About

The trial investigates the best preventive treatment approach for non-flow-limiting vulnerable plaques in patients with coronary artery disease and acute coronary syndromes. It aims to determine whether adding interventional therapy to optimal drug treatment can improve patient outcomes. The study is a randomized controlled trial sponsored by Beijing Anzhen Hospital, focusing on patients aged 18 to 80 years with specific heart conditions confirmed by imaging. Participants are randomly assigned to one of two groups. The experimental group receives interventional therapy where all vulnerable plaques are treated with second-generation drug-eluting stents followed by about 12 months of dual antiplatelet therapy, alongside optimal medical therapy including lifestyle changes and intensive lipid-lowering treatment. The control group receives only the optimal medical therapy, which involves lifestyle improvements and high-dose statins or similar drugs to reduce LDL cholesterol levels. Throughout the study, participants will be closely monitored for up to 24 months. Researchers will assess outcomes such as target vessel failure, death, heart attacks, revascularization procedures, hospitalizations, strokes, bleeding events, and symptoms like angina. The study includes thorough imaging assessments, laboratory tests, and clinical evaluations to track health status and treatment effects during treatment and follow-up periods.

Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques